In this issue:
EPOCH-R vs R-CHOP in DLBCL
Late relapse in immunochemotherapytreated DLBCL
PET for prognosis in early Hodgkin lymphoma
Intermittent vs continuous PEG-asparaginase
Ibrutinib for R/R primary CNS lymphoma
Quizartinib vs chemo in R/R FLT3-ITD AML
Polatuzumab vedotin + immunochemotherapy in DLBCL
TKI de-escalation vs discontinuation in CML
Venetoclax efficacy influenced by disease and response variables
Pembrolizumab for Hodgkin lymphoma after ASCT
Please login below to download this issue (PDF)